prednisolone has been researched along with Bile Duct Diseases in 10 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
Bile Duct Diseases: Diseases in any part of the ductal system of the BILIARY TRACT from the smallest BILE CANALICULI to the largest COMMON BILE DUCT.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with ursodeoxycholic acid (UDCA), subsequently added to the immunosuppressive therapy, apparently normalized the levels of biliary tract enzyme and total bilirubin." | 5.31 | Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid. ( Chiba, T; Fukai, K; Imazeki, F; Kanda, T; Nishimura, M; Saisho, H; Saito, Y; Yokosuka, O, 2002) |
"Among 103 patients with treated type 1 AIP, 44 (42." | 1.51 | Pancreaticobiliary involvement in treated type 1 autoimmune pancreatitis: Imaging pattern and risk factors for disease relapse. ( Asbach, P; Denecke, T; Hamm, B; Jin, ZY; Lai, YM; Tan, B; Wang, Q; Xue, HD; Zhang, W; Zheng, WY; Zhu, L, 2019) |
"However, disease relapse is common in long-term follow-up, despite a successful initial treatment response." | 1.48 | Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. ( Cho, DH; Jun, JH; Kim, MH; Lee, HW; Lee, SK; Lee, SS; Moon, SH; Nam, K; Park, DH; Seo, DW; Song, TJ, 2018) |
"Treatment with ursodeoxycholic acid (UDCA), subsequently added to the immunosuppressive therapy, apparently normalized the levels of biliary tract enzyme and total bilirubin." | 1.31 | Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid. ( Chiba, T; Fukai, K; Imazeki, F; Kanda, T; Nishimura, M; Saisho, H; Saito, Y; Yokosuka, O, 2002) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 2 (20.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 4 (40.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
Authors | Studies |
---|---|
Zhu, L | 1 |
Xue, HD | 1 |
Zhang, W | 1 |
Wang, Q | 1 |
Tan, B | 1 |
Lai, YM | 1 |
Zheng, WY | 1 |
Asbach, P | 1 |
Hamm, B | 1 |
Denecke, T | 1 |
Jin, ZY | 1 |
Saito, M | 1 |
Akutsu, N | 1 |
Numata, Y | 1 |
Ishigami, K | 1 |
Sasaki, S | 1 |
Nakase, H | 1 |
Lee, HW | 1 |
Moon, SH | 1 |
Kim, MH | 2 |
Cho, DH | 1 |
Jun, JH | 1 |
Nam, K | 1 |
Song, TJ | 1 |
Park, DH | 1 |
Lee, SS | 2 |
Seo, DW | 1 |
Lee, SK | 1 |
Fong, M | 1 |
Boyle, S | 1 |
Gutta, N | 1 |
You, MW | 1 |
Kim, JH | 1 |
Byun, JH | 1 |
Kim, HJ | 1 |
Lee, MG | 1 |
Chiba, T | 1 |
Yokosuka, O | 1 |
Kanda, T | 1 |
Fukai, K | 1 |
Imazeki, F | 1 |
Saisho, H | 1 |
Nishimura, M | 1 |
Saito, Y | 1 |
Yamanouchi, J | 1 |
Yokota, E | 1 |
Yamauchi, Y | 1 |
Matsumoto, I | 1 |
Kikuchi, K | 1 |
Miyakawa, H | 1 |
Abe, K | 1 |
Fujikawa, H | 1 |
Horiuchi, T | 1 |
Nagai, K | 1 |
Kako, M | 1 |
Chujo, S | 1 |
Sakamoto, C | 1 |
Ohno, S | 1 |
Morimoto, S | 1 |
Miyamoto, M | 1 |
Okano, H | 1 |
Morita, S | 1 |
Saeki, S | 1 |
Oimomi, M | 1 |
Fujimori, T | 1 |
Esquivel, CO | 1 |
Jaffe, R | 1 |
Gordon, RD | 1 |
Iwatsuki, S | 1 |
Shaw, BW | 1 |
Starzl, TE | 1 |
10 other studies available for prednisolone and Bile Duct Diseases
Article | Year |
---|---|
Pancreaticobiliary involvement in treated type 1 autoimmune pancreatitis: Imaging pattern and risk factors for disease relapse.
Topics: Adult; Aged; Autoimmune Pancreatitis; Bile Duct Diseases; Biomarkers; Drug Administration Schedule; | 2019 |
Development of anti-centromere antibody-positive autoimmune hepatitis after childbirth.
Topics: Adult; Antibodies, Antinuclear; Bile Duct Diseases; Biopsy; Female; Hepatitis, Autoimmune; Humans; P | 2020 |
Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Bile Duct Diseases; Calculi; Exoc | 2018 |
Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Diseases; Brentuximab Vedotin; Cycl | 2019 |
Relapse of IgG4-related sclerosing cholangitis after steroid therapy: image findings and risk factors.
Topics: Adult; Aged; Bile Duct Diseases; Cholangiography; Cholangitis, Sclerosing; Female; Humans; Immunoglo | 2014 |
Hepatic graft-versus-host disease resembling acute hepatitis: additional treatment with ursodeoxycholic acid.
Topics: Acute Disease; Adult; Bile Duct Diseases; Bone Marrow Transplantation; Cholagogues and Choleretics; | 2002 |
[A case of Sjögren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy].
Topics: Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Autoimmune Diseases; Bile Duct Diseases; Fe | 1998 |
Vanishing bile duct syndrome associated with chronic EBV infection.
Topics: Adult; Anti-Inflammatory Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Chronic Disease; Epst | 2000 |
Pericholangitis with ulcerative colitis following autoimmune hepatitis over 12 years.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Autoimmune Diseases; | 1992 |
Liver rejection and its differentiation from other causes of graft dysfunction.
Topics: Bile Duct Diseases; Chemical and Drug Induced Liver Injury; Chickenpox; Child; Child, Preschool; Cyt | 1985 |